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Clinical trials still represent the gold standard in testing the safety and efﬁcacy of new and existing
treatments. However, developing regions including sub-Saharan Africa remain underrepresented in
pharmaceutical industry sponsored trials for a number of reasons including fear of corruption and un-
ethical behaviour. This fear exists both on the part of pharmaceutical companies, and investigators
carrying out research in the region. The objective of this research was to understand the ethical con-
siderations associated with the conduct of pharmaceutical industry sponsored clinical trials in sub-
Saharan Africa.
Corruption was identiﬁed as a signiﬁcant issue by a number of stakeholders who participated in semi-
structured interviews and completed questionnaires. Additionally, fear of being perceived as corrupt or
unethical even when conducting ethically sound research was raised as a concern. Thus corruption,
whether actual or perceived, is one of a number of issues which have precluded the placement of a
greater number of pharmaceutical sponsored clinical trials in this region.
More discussion around corruption with all relevant stakeholders is required in order for progress to
be made and to enable greater involvement of sub-Saharan African countries in the conduct of industry
sponsored clinical trials.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
1.1. Introduction
Clinical trials are the mainstay in new drug development pro-
cesses, as well as for product license extensions for existing ther-
apies [1]. Despite the fact that developing countries are usually
under-represented in research due to a lack of commercial
viability and trained researchers, Africa is emerging as an important
destination for clinical trials [2]. Sub-Saharan Africa has largely
been excluded from industry sponsored clinical trials for a number
of reasons. Whilst many of these reasons are related to commercial
and practical concerns, there are also a number of ethical issues
which have precluded the placement of industry sponsored
research in this region to date. These issues include concerns
around the appropriate mechanisms for delivering informed. Egharevba).
Inc. This is an open access article uconsent, fear of being considered exploitative particularly with the
conduct of randomised placebo-controlled studies, as well as other
considerations around continued access to medicines once the
trials are complete [3,4].
The use of placebo in clinical trials is an arguably contentious
beneﬁt of conducting research in developing countries. On one side
placebo-controlled trials are easier to implement in developing
countries due to less availability of standard of care treatments and
a greater number of treatment naïve patients and thus the ability to
produce less ambiguous data which might reduce the time it takes
to approve a new drug [5]. However, there are obvious ethical
concerns with conducting studies in developing countries which
would not be approved in developed countries and it could be
argued that the conduct of such researchwould only be appropriate
if reduced timelines to drug availability would be relevant for
participating subjects. This is an important point to consider as
there are a number of examples of drugs which have not been
marketed in the developing countries in which they were tested.
Limaye et al. assessed the relationship between the number of
clinical trials conducted and the number of new drug approvalsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tween the number of studies conducted and marketed availability
of these new drugs in these two developing countries. The study
concluded that of trials conducted with sites in India and South
Africa, approximately 40% and 60% respectively led to a market
authorisation in the EU or US without an approval in India or South
Africa [6]. Homedes & Ugalde discuss similar issues in Latin
American countries where sponsor organisations have conducted
pivotal clinical trials and either failed to subsequently market the
drug in that country or have marketed the drug at a prohibitively
high cost, precluding access to treatment for many patients in that
country [7].
Another signiﬁcant concern on the part of pharmaceutical
companies, however, is that of corruption. The African Develop-
ment Bank estimate that corruption costs the continent of Africa
around $148 billion per year [8]. In comparison, developed coun-
tries gave $22.5 billion in aid to sub-Saharan Africa in the year 2008
[9]. These concerns around corruption and the associated impli-
cations for patient safety, data integrity, and the industry's repu-
tation have all played some role in preventing pharmaceutical
companies from placing more clinical trial work in the region,
despite Africa's strengthening healthcare systems and growing
economies. There are equally, however, concerns around corrupt or
unethical industry practices on the part of healthcare professionals
based in the region. These concerns are particularly relevant for
countries where there are historical cases of pharmaceutical cor-
ruption. For example, in Nigeria where the impact of the menin-
gococcal meningitis outbreak and subsequent trial of trovaﬂoxacin
by Pﬁzer [10] in 1996 duringwhich 11 children died andmanymore
were left disabled after receiving the experimental treatment tro-
vaﬂaxin (Trovan) received much attention [11]. More recent ex-
amples of unethical behaviour in the conduct of clinical trials in
developing countries include that of a trial which ran from 1997 to
2003 in Uganda sponsored by Boehringer Inglheim who were
testing nevirapine for the treatment of HIV. During this trial in-
vestigators failed to obtain patients' consent regarding changes in
the experimental design and administered incorrect doses of the
drug [12]. More recently the DART trial conducted in Uganda,
Zimbabwe and the Ivory Coast which compared structured treat-
ment interruption (STI) with continuous therapy (CT) in patients
receiving anti-retroviral therapy for the treatment of HIV high-
lighted unethical behaviour wherein patients who were on the STI
arm of the trial were not switched back to the CT arm of the trial,
despite the Data Safety Monitoring Board (DSMB) ﬁnding that
treatment interruption was associated with a higher risk of disease
[12].
Clinical trials can potentially play an important role in helping to
contribute to the development of a country's healthcare system in a
number of ways including raising research standards, exposing
physicians to new diagnosis and treatment modalities and bringing
health improvements as well as badly needed investment [13].
Angwenyi and colleagues describe the beneﬁts of investment from
clinical trials in studies that were conducted in Ghana, Kenya and
Burkina Faso, summarising how all three countries beneﬁted from
upgrades and renovations to the physical infrastructure, additional
medical supplies and medical equipment [14]. It is also important,
however, to note that despite the potential collateral beneﬁts of
clinical trials, the beneﬁt of faster access to drugsmay not always be
relevant as a recent paper by Hay et al. reported that only 10.4% of
drugs entering into phase I clinical trials are approved by the US
Food & Drug Association [15]. However, in order for sub-Saharan
Africa to increase its footprint in the clinical trial space, the topic
of corruption, whether actual or perceived, and its associated
impact on data quality, patient safety and pharmaceutical
engagement in the region needs to be further explored, understoodand addressed. Whilst corruption represents just one of a number
of challenges related to conducting trials in the region, it represents
arguably one of the most signiﬁcant and therefore needs to be
addressed before other more practical topics can be discussed.
1.2. Objectives
This is part of a larger study of stakeholders' views on the
beneﬁt, if any, to the population and the ethical implications of
conducting industry sponsored clinical research in the sub-Saharan
region of Africa.
This article presents those research ﬁndings which are associ-
ated speciﬁcally with corruption and unethical behaviour.
2. Methods
The study involved two parts. Since there is little research on
views of stakeholders interviews were conducted to explore issues.
These were than used to develop a questionnaire.
2.1. Choice of countries
For the interviews Nigeria and Ghana were chosen as the two
sub-Saharan countries fromwhich health care professionals would
be contacted due to their size, economic status, and relative sta-
bility at the time the research was planned. Existing links to health
care professionals also existed Pharma respondents were in Europe
(UK & Switzerland) and South Africa. For the questionnaire study
the countries targeted for pharma respondents were the UK, US,
and Switzerland however through snowballing questionnaires
from pharma were also completed in France and Spain. For the
healthcare professional group the countries in Africa were
expanded to include were expanded to include South Africa how-
ever through snowballing respondents from Uganda, Egypt, and
Liberia also completed the questionnaire.
2.2. Chronic versus infectious
The reasons chronic diseases were chosen are twofold; ﬁrstly,
there is evidence within the literature which illustrates increasing
levels of chronic disease in the region [15,16]. Secondly, infectious
disease rates are higher in developing countries (and therefore
unbalanced when compared to the disease proﬁle of Western
countries). In order to compare the issues related speciﬁcally to the
conduct of trials in a like for like manner, focusing on chronic dis-
ease allows comparison of patients in both the developed and
developing world.
2.3. Identifying stakeholders
Two groups of stakeholders were involved; industry pro-
fessionals and health care professionals in the relevant countries.
Stakeholders were identiﬁed from a variety of sources including
literature reviews and internet searches. For healthcare pro-
fessionals this was largely done through academic journal review
contributions. No speciﬁc journals were targeted however search
efforts focused on contributors to articles related to clinical trials
conducted in patients in Ghana and Nigeria. Healthcare advocacy
and government websites were used to identify potential govern-
ment respondents. Some stakeholders from the pharmaceutical
group were identiﬁed through existing professional links as well as
via snowballing techniques. Although not speciﬁcally targeted,
snowballing also led to the inclusion of a Non-Government Orga-
nisation (NGO) respondent with experience in clinical trials.
For the interviews, senior pharmaceutical representatives
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to be most inﬂuential on the direction of their respective organi-
sations and therefore have greater inﬂuence on the direction of the
industry as a whole.
For the questionnaire, respondents from the same group of
stakeholders were contacted, although the requirement for pharma
respondents to be senior was relaxed. This criterion was relaxed as
it was felt that senior staff members were more likely to inﬂuence
the direction of their respective companies and therefore have a
greater inﬂuence of the direction of the industry as a whole. As the
issues which senior pharmaceutical representatives believed to be
most relevant had already been elucidated during the interviews,
the aim of the questionnaire was to explore those themes in greater
detail. Additionally, relaxing the criterion allowed for a greater
number of respondents from various functional areas to be iden-
tiﬁed and approached.
2.4. Interviews
A semi-structured interview was developed based on issues
raised in academic papers, industry press and past informal con-
versations with colleagues. It was piloted with a few industry
colleagues.
2.4.1. Contacting stakeholders
Potential interviewees were contacted by email with a copy of
the Research Participant Letter of Invitation which outlined the
study in more detail and explained what would be required in the
event they chose to participate in the study.
2.4.2. Interview conduct
Due to the distances involved semi-structured interviews were
conducted either by telephone, Skype, or face to face and recorded
using a Dictaphone. Each interviewee was informed that their re-
sponses would be recorded and transcribed and asked to provide
informed consent before recording began. Interviewees were
questioned about the ethical issues that they associated with the
conduct of clinical trials in sub-Saharan Africa. All interviews were
conducted in English.
A copy of the interview schedule can be found in Appendix I.
2.5. Questionnaires
A questionnaire was developed created using the thematic
outputs from the interviews, resulting in 21 questions. It was
piloted with several pharmaceutical industry colleagues and minor
amendments were made following feedback. Changes were mostly
typographical and grammatical. Some changes were required
additional language to be added for clarity. The questionnaire could
be reached online and was hosted by Survey Monkey.
A copy of the questionnaire can be found in Appendix II.
2.5.1. Contacting stakeholders
Potential respondents were contacted by email. The email
contained a short outline of the study and included an ethics
approved plain language statement which contained more detailed
background information as well as information related to what
would be required if they decided to participate in the study. The
email also contained a direct link to the questionnaire.
Consent was taken as implied by the return of the questionnaire.
2.6. Analysis
2.6.1. Interviews
The data from the audio recordings were analysed usingthematic analysis facilitated by the use of a qualitative data analysis
(QDA) computer software package, Nvivo®. The resulting codes
were sorted into themes. In some instances codes fell into multiple
theme categories. Using the codes that fell under each of the
initially identiﬁed overarching categories, a number of more
detailed themes were derived. The initial coding was performed by
EE and then reviewed by JA and a colleague. There were no dis-
crepancies identiﬁed. Only the themes related to corruption are
considered in this paper.
2.6.2. Questionnaires
Outputs from the survey software were transferred into Nvivo®
and thematic analysis was performed on any free response com-
ments which were submitted alongside questions. Basic calcula-
tions were performed on the numeric outputs of each question for
the purpose of descriptive statistics.
2.7. Ethical approval
Ethical approval for the study was given by University of Glas-
gow College of Medical, Veterinary and Life Sciences Research
Ethics Committee.
3. Results
Only results relating to corruption and/or unethical behaviour
are presented here.
3.1. Interviews
3.1.1. Respondents
Ninety-eight emails were sent out to various stakeholders from
whom twenty-two responses (22%) were received. After further
contact sixteen (16%) interviews were conducted. A breakdown of
the number of planned and actual interviewees can be found in
Table 1. High level information of each respondent can be found in
Table 2.
Most of the interviewees fell into one of two groups; Health Care
Professionals based in Ghana or Nigeria, or pharmaceutical pro-
fessionals. Only one government respondent was involved in the
interviews.
3.1.1.1. Pharma respondents. At the time of interview, all re-
spondents in the pharma stakeholder group worked at manager
level or above and had roles in the research and development arm
of their respective organisation. Most (n ¼ 8 or 89%) held a position
equivalent to Associate Director or above. One respondent, whilst
currently not working for a pharmaceutical organisation, had done
so previously and at the time of interview was working for an NGO
whichmanages and develops a research and development portfolio
and was therefore deemed suitable for interviewing.
3.1.1.2. HCP respondents. Five out of the six respondents (83%)
falling under this stakeholder category were physicians. The one
respondent who was not a physician was a patient facing member
of clinic staff (i.e. a member of staff who is not a medic but still has
direct interaction with patients). This persons responsibilities were
to perform basic tasks associated with collecting patient samples
for research trial participants. All were based in either Ghana or
Nigeria.
3.1.1.3. Government/policy maker respondents. Despite contacting
six individuals within this particular stakeholder group, only one
responded and was interviewed. The interviewee was based in
Ghana and was working for the country's Food and Drugs Board.
Table 1
Number of planned and actual interviewees.
Stakeholder group Number from Nigeria
(planned)
Number from Nigeria
(Actual)
Number from Ghana
(planned)
Number from Ghana
(Actual)
Total
(planned)
Total
(Actual)
Government representatives 2 0 2 1 4 1
Local HCP's 3 3 3 3 6 6
Patient advocacy group
representatives
2 0 2 0 4 0
Pharmaceutical industry
representatives
e e e e 10 9
Total 24 16
Table 2
High level overview of interview participants.
Unique identiﬁer Role Years in current role Clinical trial experience? Method of interview Location
HCPN_1 Physician/Clinical Pharmacologist 10þ Yes e as Research Physician Skype Nigeria
HCPN_2 Radiologist 30þ Yes e as Research Physician Telephone Nigeria
HCPN_3 Surgeon 15þ No Telephone Nigeria
HCPG_1 Radiographer 20þ Yes Telephone Ghana
HCPG_2 Research Fellow 15þ Yes Telephone Ghana
HCPG_3 Clinical Oncologist 15þ Yes Telephone Ghana
REG_1 Food & Drugs Board 10þ Yes e Regulatory Telephone Ghana
PHARM_1 CEO Strategy & Business Development 20þ Yes e Pharma Face to face UK
PHARM_2 Operational Leader [Pharmaceutical Company] 10þ Yes e Pharma Face to face UK
PHARM_3 Non-executive Chairman, [Clinical Research Organisation] 20þ Yes e Pharma Skype South Africa
PHARM_4 Operational Leader, [Pharmaceutical Company] 20þ Yes e Pharma Face to face UK
PHARMA_5 Executive Director, Operations, [Pharmaceutical Company] 5þ Yes e Pharma Face to face UK
PHARMA_6 Medical Research Manager, [Pharmaceutical Company] 15þ Yes e Pharma Telephone UK
PHARMA_7 Interim Clinical Director, [Pharmaceutical Company] 15þ Yes e Pharma Telephone UK
PHARMA_8 Medical Director, [Pharmaceutical Company] 20þ Yes e Pharma Telephone UK
PHARMA_9 Head of Translational Medicine, [Non-Proﬁt Foundation] 15þ Yes e Pharma Telephone Switzerland
1 Identiﬁer left out to protect anonymity of respondent due to sensitive nature of
comment.
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Corruption was identiﬁed as a signiﬁcant barrier to the conduct
of clinical trials in sub-Saharan Africa across stakeholder groups.
The types of corruption that stakeholders were concerned about
differed based on which stakeholder group the interviewee fell
into.
3.1.2.1. Perception of corruption. Pharmaceutical industry stake-
holder members were concerned about not just the corruption
which could occur during the set-up and conduct of the trial but
also held fears around perceptione in particular being perceived as
corrupt and/or exploitive even when conducting ethically sound
research.
I know there's been a number of countries who have … very
high proﬁle criticism for having been accused of exploiting
populations. Some of this has been well grounded but it has
caused a lot of concern about reputation risk about being seen to
be exploiting a population who may be considered vulnerable
based on their background or education. And the reputational
risk is so high that it’s actually not worth taking.” (PHARM_8)
“Because you do a study where there may … not be ethical
concerns but ethical issues which are addressed … the fear is
that they'll just get … be spun out of context which wouldn't
happen in a European or North American or even an Asian
environment. And so there's this fear of reputational damage by
doing legitimate clinical research in a developing country such
as many of those in sub-Saharan Africa.” (PHARM_8)
During a number of interviews, pharmaceutical stakeholders
(i.e. those working in the pharmaceutical industry) raised the issue
of whether or not the idea of signiﬁcantly higher levels of corrup-
tion in sub-Saharan Africa is a perception or a reality. Apharmaceutical industry respondent who was actually based in
sub-Saharan Africa substantiated the claims from other pharma-
ceutical stakeholders around corruption but argued that it is for the
individuals involved to decide whether or not to participate in it,
describing it as being exaggerated in some instances.
“There is corruption. I'll be open about that. And it depends on
whether you participate in it or not. Whenever I went to a
Ministry of Health and they've said; ‘well what will you pay us
for this? […] We've got to get over this misconcep … it's a
conception and a misconception of corruption in the rest of
Africa.” (PHARM_X1)3.1.2.2. Responsibility of pharmaceutical companies. The complexity
of issues around corruption became evident when discussions
progressed onto the topic of the structure of pharmaceutical
companies. Publicly traded companies have a responsibility to
shareholders and the importance of ensuring their buy-in to any
efforts to engage countries perceived as corrupt was a topic which
was raised through the interviews as well. The amount of resource
required to track the ﬂow of equipment and investigational product
was also a topic that was raised. This is relevant particularly when
considering the earlier referenced transparency index metrics, an
objective measure of corruption, for the countries who were rep-
resented by those involved in these interviews [9].
“… you know and you hear, you know, evenwith aid that's been
given you hear about it being misappropriated and going to …
and that isn't going to resonate well with shareholders if you
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and then, you know, you've got to actually track it. It's not just
enough to make a donation, you have to check it's actually
getting to where you think it's supposed to be getting and stuff
like that.” (PHARM_4)
Concerns of corruptionwere not just directed toward those who
are involved in the region. Several pharmaceutical interviewees
were critical of the industry and raised issues around the potential
for pharmaceutical companies to behave in a corrupt way if
working outside the more closely regulated conﬁnes of the West's
regulatory and ethical oversight;
“… basically I would think that the major pharmaceutical
companies in the West are behaviourally very poor. They are
extremely cynical in the way that they conduct studies in the
West, in the way they publish data in the West, and do not
publish data where they withhold data. The way they manipu-
late clinical studies to profoundly alter the outcome of those
medicines to make them much more favourable than they
would otherwise be. If they were doing this in third world
countries, they probably would do more of that.” (PHARM_1).
“… although I do work in the pharmaceutical industry, I am
quite cynical that no successful pharmaceutical companies
operate within a capitalist society where they're out to make,
you know…where their reason for being is tomake a proﬁt and
my personal view is sometimes apparently philanthropic acts
that pharmaceutical companies announce are really attempts to
you know, they're marketing attempts to make them look good
so at the end of the day you know there's the potential … you
know the proﬁt might not be there but the proﬁt's there in
intangible assets”. (PHARM_7)
3.1.2.3. Historical corruption. Health care professionals were
focussed on the troubling history of clinical trials in developing
countries. There are high proﬁle historical examples of pharma-
ceutical companies behaving inappropriately in developing coun-
tries. Just as some pharmaceutical representatives had concerns
that stakeholders involved in the trial process in sub-Saharan Africa
may not behave ethically, healthcare professionals in the region
also had their own concerns about potential corruption on the part
of pharmaceutical companies. These fears around the legacy of
corruption in Africa and its potential consequences on the conduct
of ethically sound clinical research in the region suggest that trust is
a mutual concern and will be an important factor if countries in
sub-Saharan Africa are to participate in more industry sponsored
research;
… there is an issue of trust and an issue of exploitation or non-
exploitation. People are usually really suspicious you know but I
think you need a lot of public enlightenment and you need very
good policy structure in place which can be enforced because
now the problemwith most of sub-Saharan Africa… Nigeria, let
me use Nigeria for example is that you have very good policies
but they're not enforced. So people come in and do whatever,
like the Pﬁzer trial that took place in Nigeria some years ago that
was very scandalous. (HCPN_1)
“Most people in Nigeria just think that if you say ‘trial’, they'll
say ‘oh they're using you for guinea pigs’ OK?” (HCPN_1)
3.1.2.4. Unethical behaviour of healthcare professionals. There wasrecognition on the part of the healthcare professionals based in the
region that they were perceived by some externally as corrupt.
Comments suggested that some of the training groups operating in
the region have started to include discussions around transparency
and corruption as part of the training provided to further educate
potential researchers.
“… so they have no reason not to understand the importance of
being absolutely precise inwhatever they're doing and to report
exactly what they are doing and not to doctor results and the
importance of the informed consent process and that it’s not
just a document for participants to sign, but a document for you
to ensure that they understand everything that is within the
informed consent, it's a process, rather than just a, you know, a
mere signature, bribe type of event. So they know all this and
they understand all of this …” (HCPN_2)
Healthcare professionals based in the region also expressed
concern regarding the potential for healthcare professionals to
coerce potential trial subjects into a study which may not be right
for them. The socioeconomic conditions which exist in many parts
of this region make subjects more susceptible to being unduly
coerced and potentially impact a potential subject's ability to make
an informed decision in the presence of an insistent investigator.
Investigators may stand to beneﬁt from enrolling as many patients
as possible into clinical trials for a number of reasons, for example
for ﬁnancial gain or professional notoriety etc.
“Again for sub-Saharan Africa why it's particular is because you
have a group of vulnerable people and when I mean vulnerable
people I'm not thinking about children or women or pregnant
women alone or disabled or prisoners, I'm thinking of …
because of the economic problems I actually put Africans as
vulnerable and especially when it comes to research because
most of the people you're going to be doing the research with…
the clinical research, the clinical trials, they're not the people in
the blue chip companies in their ofﬁces, you're going to go to the
communities and these are the people that are poor, that are
managing to survive so any help, in quotes, that they are getting
from you, you're not sure if you're inducing them or not.”
(HCPN_1).
This susceptibility to coercion is also made worse by the dy-
namics of the physician: patient relationship in this part of the
world where doctors enjoy a higher social standing and are
therefore less likely to be challenged by their patients.
“… because in this part of the world most patients just believe
that the doctor knows what is best for them so when you tell
them that; “OK, so I'm doing this study, do you want to join?”
they'll tell you “Ah, doctor, you knowwhat is best for me e I will
do it!” (HCPN_1).
Transparency and open dialogue from investigators is one way
through which this behaviour can be countered and trust can be
built with patients in the region, particularly following incidents
such as the trovaﬂaxin (Trovan) trial which increase the levels of
distrust.
So, now, when you tell people that OK, this is essential for your
health or for the health of your children. That the drugs we're
using now are not working. You need to get new drugs and this
is the only way you can ﬁnd out so I think you just need to talk to
people. Once you talk to them and you assure them that their
health and safety is taken care of and theywill get insurance and
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of people will… because I've done trials, like I told you with my
boss before and you see most times once you talk to them, they
agree. They agree, but again you need to build trust.” (HCPN_2)
The topic of corruption and unethical behaviour is a complex
one. The results from the interviews evidenced mutual suspicion
and concern on the part of both pharmaceutical companies in the
West and healthcare professionals based in Ghana and Nigeria. The
concerns around corruption appear to be genuine although
potentially exaggerated, however historical examples on the part of
the pharmaceutical companies such as the Pﬁzer Trovan incident in
Kano, Nigeria are still recent enough to cause concern for some of
those treating patients in sub-Saharan Africa.
3.2. Questionnaire
3.2.1. Respondents
Two-hundred and thirty-seven emails were sent out to potential
respondents and seventy-ﬁve questionnaires were eventually
completed (32%).
Of the 75 respondents, the largest percentage, 77% (n¼ 58) were
from the pharmaceutical industry followed by 15% (n ¼ 11) from
healthcare professionals and 4% (n ¼ 3) were from a group which
was labelled other but included; a Lawyer, Investment Director and
a Managing Consultant. The regulatory group comprised only a
small percentage of those surveyed (1%, n ¼ 1).
3.2.2. Themes
Five questions were related to corruption and unethical
behaviour and are presented here. The quantitative responses for
these questions are given in Table 3. Each question gave re-
spondents the opportunity to comment, those relevant to the
theme of corruption are presented as theywere entered (verbatim).
3.2.2.1. Corruption and/or fraud are NOT likely to impact the conduct
of clinical trials in sub-Saharan Africa. The ﬁrst question related to
corruption asked respondents to indicatewhether they agreedwith
a statement which suggested that corruption and fraud were un-
likely to impact the conduct of clinical trials in sub-Saharan Africa.
The results indicate that fraud is perceived to be a signiﬁcant po-
tential issue as (63%, n¼ 47) either strongly disagreed or disagreed.
Of the four respondents who agreed (n ¼ 3) or strongly agreed
(n ¼ 1), only one respondent was an HCP based in sub-Saharan
Africa.
Disagree;Table 3
Responses to questionnaire questions related to corruption and unethical behaviour.
1. Corruption and/or fraud are NOT likely to impact the conduct of clinical trials in sub
Saharan Africa
2. Pharmaceutical companies are likely to exploit patients involved in clinical trials in su
Saharan Africa.
3. Investigators (clinicians) in sub-Saharan Africa are more likely than those in theWest
exploit patients in clinical trials.
4. Investigators in sub-Saharan Africa are more likely than those in theWest to falsify da
for ﬁnancial gain.
5. Pharmaceutical companies in the West do not always conform to GCP
6. Pharmaceutical companies do not want to engage in research in sub-Saharan Africa ov
fears of being considered exploitative.
Most common response is bolded.“Unfortunately, some persons are motivated by proﬁted and
would aim for proﬁt at any cost. The tobacco industry comes to
mind” (REG/HCP)
“Corruption is a universal thing” (HCP(2))
Neutral;
“The (sic) hits all walks of life” (PHARM(57))
The universality of corruption and fraud at numerous levels was
a sentiment which was echoed throughout the supplementary
comments. Many respondents lacked experience working in the
region, however the role of the media in shaping the perception of
those in the West was also evident.
Disagree;
“Without ﬁrsthand (sic) knowledge I cannot say with any cer-
tainty but my impression from media representation of the re-
gion is that governmental corruption is rife and assuming that to
be correct I would assume it could extend to the regulatory
environment and healthcare services that might be involve in
trials.” (PHARM(11))3.2.2.2. Pharmaceutical companies are likely to exploit patients
involved in clinical trials in sub-Saharan Africa. In response to this
question 43% (n ¼ 32) of respondents disagreed. Over a ﬁfth of
respondents either agreed (13%, n ¼ 10) or strongly agreed (8%,
n ¼ 6) with the statement, the majority being HCPs working in the
region. This ﬁnding represents an arguably unsurprising disconnect
between the perceptions of the pharmaceutical industry between
stakeholder groups. Comments left in response to this question
point quite clearly to the Pﬁzer trovaﬂaxin (Trovan) trial as the
biggest example in recent history;
Agree;
“there are examples from Nigeria I am sure you are aware of”
(HCP(3))
There were also some respondents from the pharmaceutical
stakeholder group who believe that pharmaceutical companies are
likely to take advantage of clinical trial subjects in developing
countries. This echoed some of the comments made during the
interview part of study.1 (strongly
disagree)
2
(disagree)
3
(neutral)
4 (agree) 5 (strongly
agree)
Responses Average
- 15 (20%) 32 (43%) 24 (32%) 3 (4%) 1 (1%) 75 2.24/5
b- 13 (17%) 32 (43%) 14 (19%) 10 (13%) 6 (8%) 75 2.52/5
to 8 (11%) 21 (28%) 26 (35%) 17 (23%) 2 (3%) 74 2.78/5
ta 7 (10%) 24 (33%) 22 (30%) 17 (23%) 3 (4%) 73 2.79/5
7 (10%) 24 (33%) 17 (23%) 22 (30%) 3 (4%) 73 2.86/5
er 2 (3%) 21 (28%) 23 (31%) 26 (35%) 3 (4%) 75 3.09/5
2.71/5
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“I would like to disagree with this - but can't!” (PHARM(20))
3.2.2.3. Investigators (clinicians) in sub-Saharan Africa are more
likely than those in the West to exploit patients in clinical trials.
In response to the next statement suggesting that investigators
treating clinical trial patients in developing countries were more
likely than their counterparts in the West to exploit patients in
clinical trials, 39% (n¼ 29) of respondents either strongly disagreed
(11%, n¼ 8) or disagreed (28%, n¼ 21). 35% of respondents (n¼ 26)
were neutral whilst 23% (n¼ 17) and 3% (n¼ 3) agreed and strongly
agreed, respectively. The overall results suggested that HCPs mostly
disagree with the statement. There were, however, some HCP re-
spondents who strongly agreed (n ¼ 1) and agreed (n ¼ 3) with the
statement.
Disagree;
“I think investigators will exploit patients (if given the oppor-
tunity) anywhere.” (PHARM(32))
Neutral;
“I hope/ don't think therewould be an intent to do this on awide
basis but societal norms are different and this would be likely to
inﬂuence some investigators” (PHARM(44))
This is relevant because one could argue that there is an element
or aspect of corruptionwhich is subjective. This will be discussed in
further detail later on in this article.
3.2.2.4. Investigators in sub-Saharan Africa are more likely than
those in the West to falsify data for ﬁnancial gain. Of the seventy-
three respondents who responded to the question asking them to
indicate their agreement with the following statement; In-
vestigators in sub-Saharan Africa are more likely than those in the
West to falsify data for ﬁnancial gain, approximately 30% (n ¼ 22)
were neutral and a third (33%) disagreed with the statement. A
further 23% (n ¼ 17) and 4% (n ¼ 3) agreed or strongly agreed,
respectively, indicating that some felt investigators would poten-
tially falsify data.
Neutral;
“I think there is more motivation in any developing country to
falsify data than developed countries. I don't feel this is Africa
speciﬁc” (PHARM(45))
3.2.2.5. Pharmaceutical companies in the West do not always
conform to GCP. The next statements asked respondents to indicate
whether or not they believed that pharmaceutical companies in the
West do not always comply with GCP. Approximately a third
(n ¼ 24, 33%) of all seventy-three respondents disagreed with this
statement. A further 10% (n ¼ 7) strongly disagreed indicating that
many believe that pharma is largely compliant with GCP. However,
an observation worth noting (particularly considering the pharma
bias sample population) is that over a ﬁfth (23%, n¼ 17) agreed that
pharma does not always comply with GCP in theWest and a further
4% (n ¼ 3), all of whom fell under the pharma stakeholder group,
strongly agreed with the statement.
Disagree;“On the whole they do!” (PHARM(14))
Neutral;
“true, any audit ﬁnding is a non-conformance to GCP. But if this
question is seeking my thoughts on wilful non-conformance,
then I'd be inclined to disagree, these days” (PHARM(12))
Strongly agree;
“Fact of life, sometimes intentionally, sometimes not”
(PHARM(8))3.2.2.6. Pharmaceutical companies do not want to engage in research
in sub-Saharan Africa over fears of being considered exploitative.
The ﬁnal question around corruption and unethical behaviour
asked respondents to indicate their agreement with the following
statement; Pharmaceutical companies do not want to engage in
research in sub-Saharan Africa over fears of being considered
exploitative.
Of the seventy-ﬁve respondents, (35%, n ¼ 26) agreed with the
statement e three of these respondents fell under the HCP stake-
holder group. This was followed by 31% (n ¼ 23) who were neutral.
One respondent who was in agreement went as far as to liken (in
what may or may not be tongue in cheek) some of the people
working in the region to the secret police of Nazi Germany
commenting;
Agree;
“Agree. Many self-appointed “ethicists” in the region bear more
resemblance to the Gestapo than to Ghandi.” (PHARM(30))
Disagree;
“I do not think it is this fear that drives it, but the regulatory
expectations, ethics, and reliability of data” (PHARM(11))4. Discussion
The ﬁndings from both parts of the study will be treated
together since there was no real disparity between them. The
majority of the pharma industry respondents did not have expe-
rience of working in developing countries and the responses from
this stakeholder group should be viewed with this in mind.
Nevertheless, their views, irrespective of how they have been
reached, are likely to be important within the industry especially
given the seniority of pharma stakeholder groups involved in the
interviews.
The responses from both the interviews and questionnaires
highlight that there are still concerns from healthcare professionals
in developing countries due to the conduct of some contentious
trials in the past, more speciﬁcally the Pﬁzer Trovan trial in Nigeria
[10]. This has led to questions around pharma's presence in the
region because of the conduct of potentially unethical or corrupt
studies. Healthcare professionals also highlight patient concerns
around industry sponsored clinical trials with some believing that
they're being used as guinea pigs by pharmaceutical companies.
There appeared to be mutual suspicion between stakeholder
groups with each concerned about the other's potential behaviour
when conducting trials in sub-Saharan Africa.
On the part of pharma, there were several concerns around
corruption and unethical behaviour, the ﬁrst of these being around
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where research is conducted ethically, there is a chance that it will
still be perceived as exploitative simply because the trials are being
carried out in this developing part of the world. The inﬂuence of
media, whilst not explicitlymentioned, was evident throughout the
interviews with pharma respondents as many had not worked in
the region but had concerns based on things they had seen and
heard in the media. The power of the media to inﬂuence perception
is an important point to note on both sides the media could like-
wise inﬂuence healthcare professionals and the general public
likewise by painting pharmaceutical companies engaging in
research in this part of the world in a negative light.
Another concern on the part of pharma was around the
misappropriation of resources (e.g. equipment, payments etc.)
which may be given to hospital sites and investigators for the
conduct of trials and where they would potentially be directed to.
Although the majority of pharma representatives who were inter-
viewed and who completed the questionnaire did not have expe-
rience working in the region, many were under the impression that
there were higher levels of corruption in sub-Saharan Africa than in
Western countries. This could lead to equipment and material not
reaching its intended destination and being sold privately. It could
also lead to experimental medicines being unlawfully sold on,
which could have more serious consequences.
The research also showed that many feel as though pharma-
ceutical companies are largely compliant with ethical standards
when conducting research in the West, however there were con-
cerns even from pharma representatives themselves that com-
panies may not be so compliant when conducting trials outside of
the more closely regulated Western countries which are typically
represented in industry-sponsored clinical trials. The research also
highlighted the cynical views that members of the pharmaceutical
group hold about current industry practices which are of concern
and may indicate that current stringent regulations and self-
policing of the industry are not producing the desired results.
4.1. Recommendations for moving forward
It is important that as discussions around sub-Saharan African
countries participating in clinical trials begin to gain traction, issues
such as the potential for corruption do not become the proverbial
elephant in the room2. The ﬁndings here suggest that there is some
suspicion by all parties involved of the other groups, whether this
be around corruption or exploitation. This might suggest that dis-
cussions need to be held openly with solutions around creating
transparency and accountability mutually agreed by all parties. This
mutual agreeability is an important component to making progress
as it will demonstrate that pharma companies are avoiding the
adopting of imperialistic strategies which fail to take into account
the cultural and practical differences that exist between developing
countries and the West.
It is important to note that many companies are beginning to
take steps towards ensuring the conduct of ethical trials in devel-
oping countries and are benchmarked against one another. The
Access to Medicines Index [17] assesses companies on their
compliance to ICH-GCP standards and the Declaration of Helsinki
[18,19], as well as companies' processes for monitoring compliance
and taking disciplinary action when necessary, for both in-house
and outsourced trials. Additionally, it examines companies'
criteria for selecting Clinical Research Organisations (CROs) as well
as compliance with WHO's 2005 Technical Consultation of Clinical2 ‘Elephant in the room’ refers to an obvious problem or difﬁcult situation that
people do not want to talk about.Trial Registration Standards [20] to ensure that trials are registered
centrally and that results are published irrespective of outcomes.
The selective registering of results of trials was a concern which
was raised by a pharma respondent during the interviews and so
compliance with these guidelines will help redress this concern.
The Index's 2014 report showed that most pharmaceutical com-
panies are generally setting high standards for trial conduct with a
handful being exceptional in respect of high levels of transparency
and clinical trial codes of conduct [17]. It is worth noting, however,
that the Access to Medicines Index ratings are based on self-
reporting, and not on actual inspections of the trials.
Taking into consideration the legacy of the historic examples of
corrupt and unethical behaviour pharmaceutical companies ought
to ensure they are conducting themselves with the same level (if
not greater) of transparency and ethical integrity that they would
when conducting trials in the West. This includes developing
appropriate trial designs for this part of theworld and ensuring that
they do not compromise the health andwellbeing of patients due to
corrupt business practices and ethically questionable research.
This, along with education, two-way discussions and an appro-
priate code of conduct should help overcome the fear (and actu-
ality) of being perceived as exploitative and/or corrupt simply by
conducting research in developing countries. This will require
further discussion on sensitive topics such as corruption e more
speciﬁcally, conversation around whether or not the deﬁnition of
‘corruption’ is universally applicable or whether there are/should
be allowances from Western interpretations of corruption in
recognition of cultural or societal norms.
The countries which comprise sub-Saharan Africa are each
unique in their landscape and in their cultural norms and this
should be taken into account when engaging the relevant stake-
holders in these various countries. The only way to effectively
achieve this is to ensure those on the ground are engaged and
consulted and that ﬂexibility to allow for cultural nuances and
norms is permitted, so long as they do not compromise the health
and wellbeing of research participants nor the integrity of the data
produced.
4.2. Limitations
4.2.1. Limitations of interviews
Numbers were not as high as originally planned for and only
two of the stakeholder groups were well represented. A higher
number of interviews with a more varied group of stakeholders
based in the countries of interest might have been achieved either
by travelling to the countries (which would have been prohibitively
expensive) or recruiting a local interviewer. Whether the inter-
viewer came from a drug company, was based in the West or was
local there was the possibility they would always be seen as biased
in some way by different groups.
Another limitation was the way in which interviewees, partic-
ularly those in the HCP group, were identiﬁed. These were mostly
identiﬁed through academic journals and snowballing and as such,
can be assumed to have at least some interest in clinical research. It
would have been preferable to have had a mixed sample of HCPs
from the region (i.e. those with and without research interests)
however many of the HCPs contacted who were not identiﬁed
through other methods such as internet searches did not respond
to requests to participate in the interview. The ﬁndings may have
been different if the HCPs did not have an interest or working
knowledge of clinical research. Conversely, one could argue that
HCPs with no research interest may not have been able to identify
the relevant issues due to unfamiliarity with some of the relevant
topics. This potential bias means it is difﬁcult to ascertain whether
or not the results of this study are representative of the general
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4.2.2. Limitations of questionnaire
The low overall response rate to the questionnaire was a limi-
tation for this study. Furthermore, a similar and greater number of
respondents across each stakeholder groupwould have allowed for
a more balanced comparison. Within the pharma stakeholder
group, it would have been preferable to have had greater cross
functional representation. More speciﬁcally, the involvement of
more respondents who work in, for example, commercial opera-
tions as opposed to the almost exclusively R&D based group of
respondents who were contacted to complete the questionnaire.
Also, it is difﬁcult to know whether the responses which indi-
cated a neutral position were truly neutral or whether respondents
did not know the answer and therefore chose a neutral response. In
retrospect it may have been better to have added an option for
respondents to indicate they did not know the answer to the
question in order to gain a better understanding of how neutral
responses should be interpreted. This was not raised in the piloting
of the questionnaire.
5. Conclusions
Set against a context of under-representation in clinical trials
and raising prevalence of chronic disease in sub-Saharan Africa this
study looked at stakeholders' perceptions of corruption and un-
ethical behaviour in such trials.
The main ﬁndings around corruption which came out of this
research showed that there appears to be an element of mutual
suspicion on the part of the two stakeholder groups best repre-
sented in both parts of this research. The perception of pharma
respondents seemed to have been largely inﬂuenced by media, and
important point to note, as many did not have any experience
working in the region yet their responses indicated suspicion.
Healthcare professionals in the region were suspicious of the
pharmaceutical industry largely because of historical examples of
corruption, most notably the Pﬁzer experiments.
There were concerns on both parts that patients may be
exploited either by pharma companies conducting poorly designed
or unethical studies or by healthcare professionals falsifying data or
misappropriating resource intended for clinical trial use. Addi-
tionally, the fear of being perceived as corrupt plays a signiﬁcant
role is in precluding the placement of trials in this part of the world
as the risk of reputational damage may be greater than the reward.
Opening up the debate between pharmaceutical companies and
local stakeholders would seem to be the ﬁrst step to developing the
clinical trial research capacity in the involved countries.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.conctc.2016.04.009.References
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